SYN - Synthetic Biologics, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
0.4127
+0.0004 (+0.10%)
At close: 3:58PM EST
Stock chart is not supported by your current browser
Previous Close0.4123
Open0.4100
Bid0.4129 x 800
Ask0.4130 x 1000
Day's Range0.4003 - 0.4195
52 Week Range0.3700 - 0.9100
Volume117,372
Avg. Volume78,109
Market Cap6.936M
Beta (3Y Monthly)1.98
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire

    Sýn hf.: Landsdowne Partners International Limited - Major shareholder announcements

    See attachment: Attachment Landsdowne_191114 SYN IR

  • GlobeNewswire

    Sýn hf.: Best operating profit of the year

    At the beginning of the year, the accounting treatment of broadcasting license rights was changed, amounts for 2018 have been restated. EBITDA for the first nine months of 2019 was ISK 4,100 million, a decrease of ISK 153 million from same period in 2018. Profit in the first nine months of the year amounted to ISK 384 million which is an increase of ISK 135 million from same period in 2018.

  • Synthetic Biologics Reports Third Quarter 2019 Operational Highlights and Financial Results
    PR Newswire

    Synthetic Biologics Reports Third Quarter 2019 Operational Highlights and Financial Results

    -- Enrollment is Ongoing in Phase 2b Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C -- -- Conference Call Today, November 4, 2019, at 4:30 p.m. (EST) -- ROCKVILLE, Md. , Nov. ...

  • Synthetic Biologics to Report 2019 Third Quarter Operational Highlights and Financial Results on November 4, 2019
    PR Newswire

    Synthetic Biologics to Report 2019 Third Quarter Operational Highlights and Financial Results on November 4, 2019

    -- Conference Call Scheduled for Monday, November 4, 2019 at 4:30 p.m. ET -- ROCKVILLE, Md. , Oct. 28, 2019 /PRNewswire/ --  Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage ...

  • Synthetic Biologics Strengthens U.S. Patent Coverage of SYN-010, Intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
    PR Newswire

    Synthetic Biologics Strengthens U.S. Patent Coverage of SYN-010, Intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)

    ROCKVILLE, Md., Sept. 26, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the U.S. Patent and Trademark Office (USPTO) has granted a U.S. patent and issued a Notice of Allowance for a patent application covering various aspects of the clinical SYN-010 program. Recently granted U.S. Patent No. 10,328,151, which is co-owned by Synthetic Biologics and Cedars-Sinai Medical Center (CSMC) and exclusively licensed to Synthetic Biologics, covers the composition of matter of the SYN-010 clinical agent.

  • GlobeNewswire

    Sýn hf.: Financial results below expectations but positive outlook

    Sýn´s Q2 2019 financial statement was approved by Sýn´s CEO and Board of Directors at a board meeting on August 28, 2019. At the beginning of the year, the accounting treatment of broadcasting license rights was changed. Broadcasting license rights was classified as inventory but as of January 1, 2019, it is classified as intangible assets.

  • GlobeNewswire

    Sýn hf.: Change in guidance

    After changes in management, which occurred in the first half of the year, a new financial forecast has been implemented.  The forecasted EBITDA will be lowered since revenues in telecom and media are forecasted close to 400 million lower and cost of media content and distribution are estimated 160 million higher.  The previous forecast for free cash flow is unchanged but it is clear the result will be at the lower end of the 1,6-2,0 bn range. Management has made changes to the financial reporting process of each division and strengthen its key control procedures, which will lead to better forecasting going forward.  Measures taken this summer, which will be realized at the end of the year, have lowered the cost basis of the company.

  • Synthetic Biologics Reports Second Quarter 2019 Operational Highlights and Financial Results
    PR Newswire

    Synthetic Biologics Reports Second Quarter 2019 Operational Highlights and Financial Results

    -- Announced Clinical Trial Agreement with Washington University School of Medicine to Conduct a Phase 1b /2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients ...

  • Synthetic Biologics to Report 2019 Second Quarter Operational Highlights and Financial Results on August 8, 2019
    PR Newswire

    Synthetic Biologics to Report 2019 Second Quarter Operational Highlights and Financial Results on August 8, 2019

    -- Conference Call Scheduled for Thursday, August 8, 2019 at 4:30 p.m. ET -- ROCKVILLE, Md. , Aug. 1, 2019 /PRNewswire/ --  Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company ...

  • Synthetic Biologics Regains Compliance with NYSE American Continued Listing Standards
    PR Newswire

    Synthetic Biologics Regains Compliance with NYSE American Continued Listing Standards

    ROCKVILLE, Md., July 1, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today receipt, on June 28, 2019, of notification from the NYSE American LLC (the "Exchange") that the Company has regained compliance with Part 10, Section 1003 of the NYSE American's Company Guide (the "Company Guide") relating to the Exchange's continued listing requirements. The Company previously received notification from the NYSE American citing failure to comply with the minimum stockholders' equity continued listing standard as set forth in Part 10, Section 1003 of the Company Guide.

  • GlobeNewswire

    Sýn hf.: Notification of related party trading

    See attachment: Attachment NOMX - Viðskipti fjárhagslega tengds aðila 24 05 2019

  • Synthetic Biologics Reports First Quarter 2019 Operational Highlights and Financial Results
    PR Newswire

    Synthetic Biologics Reports First Quarter 2019 Operational Highlights and Financial Results

    -- Enrollment is Ongoing in Phase 2b Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C; Topline Data Readout Anticipated in 2H 2019 -- -- Conference Call Today, May 8, 2019, ...

  • Synthetic Biologics to Report 2019 First Quarter Operational Highlights and Financial Results on May 8, 2019
    PR Newswire

    Synthetic Biologics to Report 2019 First Quarter Operational Highlights and Financial Results on May 8, 2019

    -- Conference Call Scheduled for Wednesday, May 8, 2019 at 4:30 p.m. ET -- ROCKVILLE, Md. , April 30, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company ...

  • Synthetic Biologics Reports 2018 Year End Operational Highlights and Financial Results
    PR Newswire

    Synthetic Biologics Reports 2018 Year End Operational Highlights and Financial Results

    -- Enrollment is Ongoing in Phase 2b Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C; Topline Data Readout Anticipated in 2H 2019 -- -- Conference Call Wednesday, February ...

  • GlobeNewswire

    Sýn hf. : Q4 Investors presentation

    See attached:  Investors presentation Q4 This announcement is distributed by West Corporation on behalf of West Corporation clients. The issuer of this announcement warrants that they are solely responsible ...

  • GlobeNewswire

    Sýn hf. : Changes in management of Sýn hf.

    Stefán Sigurðsson, the CEO of Sýn hf., has in accordance with an agreement with the Board of Directors, requested to resign from his post, effective as of June 1st 2019. The Board of Directors has requested the Chairman of the Board to take on an active role as regards the organizational structure of the Company as well as ensuring that the operation of the Company will be in good order until a new CEO has been recruited. This announcement is distributed by West Corporation on behalf of West Corporation clients.

  • GlobeNewswire

    Sýn hf. : Merged company completes its first full year under challenging market conditions

    Sýn`s 2018 annual financial statement was approved by Sýn`s CEO and board of directors at a board meeting 27th of February 2019. In December 2017 the company purchased certain assets and operations of 365 Miðlar hf., and this influences the comparison between periods. Sýn and the Faroese company Tjaldur have agreed on heads of terms in the merger of P/F Hey a subsidiary of Sýn and the Faroese IT company Nema a subsidiary of Tjaldur.

  • GlobeNewswire

    Sýn hf. : Sýn finalizes the merger of Hey P/F with Nema P/F

    Reference is made to Stock Exchange announcement from November 1st 2018, according to which Sýn and the Faroese company Tjaldur had agreed heads of terms in relation to a merger of Hey, a subsidiary of Sýn, and the Faroese IT company Nema, a subsidiary of Tjaldur. This announcement is distributed by West Corporation on behalf of West Corporation clients.

  • Synthetic Biologics to Report 2018 Year End Operational Highlights and Financial Results on February 27, 2019
    PR Newswire

    Synthetic Biologics to Report 2018 Year End Operational Highlights and Financial Results on February 27, 2019

    -- Conference Call Scheduled for Wednesday, February 27, 2019 at 4:30 p.m. EST -- ROCKVILLE, Md. , Feb. 19, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company ...

  • Synthetic Biologics Announces First Two Patients Enrolled in Phase 2b Investigator-Sponsored
    PR Newswire

    Synthetic Biologics Announces First Two Patients Enrolled in Phase 2b Investigator-Sponsored

    ROCKVILLE, Md., Jan. 3, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today announced that the first two patients have been enrolled in SYN-010's Phase 2b investigator-sponsored clinical study. SYN-010 is a proprietary, modified-release reformulation of lovastatin lactone designed to reduce methane production by certain microorganisms (M. smithii) in the gut to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). Cedars-Sinai Medical Center (CSMC) and Synthetic Biologics are co-funding the study, which will further assess the efficacy and safety of SYN-010 in patients diagnosed with IBS-C.

  • GlobeNewswire

    Orchestra BioMed™ Appoints C. Evan Ballantyne as Chief Financial Officer

    Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing advanced therapeutic solutions to address major unmet medical needs, announced today that it has appointed Evan Ballantyne as its Chief Financial Officer (CFO). Mr. Ballantyne is an experienced financial and strategic leader in the biotech, medical device and information services industries with a proven track record of building and strengthening a company’s financial position during his career of more than 25 years. David Hochman, Chairman and Chief Executive Officer of Orchestra BioMed, commented, “Over the course of his career, Evan has played key roles in successfully leading companies in the full range of strategic options in financing including private equity and public offerings.

  • GlobeNewswire

    Report: Exploring Fundamental Drivers Behind Synthetic Biologics, Plexus, TG Therapeutics, Hortonworks, NorthWestern, and Archer Daniels Midland — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • ACCESSWIRE

    New Healthcare Trends Could Push Sector Stocks Higher

    CORAL GABLES, FL / ACCESSWIRE / November 21, 2018 / Healthcare stocks continue to gain traction amid volatile market conditions this week. Investors have been less optimistic on tech stocks and more favorable to the healthcare sector. US midterm elections have also helped to boost a more favorable market for healthcare.

  • Synthetic Biologics Announces Positive Outcome of End-of-Phase 2 Meeting with FDA on SYN-004 (ribaxamase) Development
    PR Newswire

    Synthetic Biologics Announces Positive Outcome of End-of-Phase 2 Meeting with FDA on SYN-004 (ribaxamase) Development

    ROCKVILLE, Md., Nov. 21, 2018 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today announced that it has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to discuss development of SYN-004 (ribaxamase) for the prevention of antibiotic-mediated Clostridium difficile infection (CDI). Pursuant to the meeting, the FDA has proposed criteria for Phase 3 clinical efficacy and safety which, if achieved, may support submission for marketing approval of ribaxamase on the basis of a single Phase 3 clinical trial.